Experiences of patient delay among lung cancer patients in South China
- PMID: 39696074
- PMCID: PMC11656902
- DOI: 10.1186/s12885-024-13295-2
Experiences of patient delay among lung cancer patients in South China
Abstract
Background: Lung cancer is a commonly diagnosed cancer and the leading cause of cancer-related mortality worldwide. Cancer delay pose significant challenges for health systems globally, with patient delay being a primary factor contributing to late diagnoses, ultimately resulting in adverse outcomes and reduced survival rates. However, the underlying reasons for patient delay are not well understood, and there is a scarcity of studies that specifically examine the experiences related to patient delay among lung cancer patients. Therefore, this study aims to explore the experiences of lung cancer patients and identify potential strategies to mitigate their delays in seeking care.
Methods: The interview framework was developed based on the Theory of Planned Behavior. Face-to-face semi-structured interviews were conducted with participants. Data analysis was performed using Colaizzi's phenomenological analysis method.
Results: A total of 30 lung cancer patients participated in the interviews, which lasted between 26 and 42 min (with an average duration of 33 min). The duration of patient delay varied from 90 to 213 days. Four themes were identified: (1) reasons for patient delay, (2) health-seeking triggers, (3) perception of patient delay, and (4) potential solutions.
Conclusion: Lung cancer patients exhibited varying degrees of patient delay attributed to factors such as ignoring or dismissing symptoms, lack of family support, poor access to health services, and the COVID-19 pandemic. Promoting disease knowledge, optimizing resources and implementing technology-based solutions may serve as effective measures to address these issues.
Keywords: Disease knowledge; Lung cancer; Patient delay; Resource optimization.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This study was approved by the Ethics Committee of the First Hospital of Guangxi Medical University (Approval No.2021-12). Each participant was assigned a number to protect their anonymity, informed consent to participate was obtained from all the participants in the AQ study. Consent for publication: Not Applicable. Competing interests: The authors declare no competing interests.
Similar articles
-
Patient perceptions of barriers to the early diagnosis of lung cancer and advice for health service improvement.Fam Pract. 2013 Aug;30(4):436-44. doi: 10.1093/fampra/cmt001. Epub 2013 Feb 1. Fam Pract. 2013. PMID: 23377608
-
Experiences of care-seeking by schizophrenia patients with delayed diagnosis and treatment in rural China: A qualitative study.Int J Soc Psychiatry. 2023 Sep;69(6):1453-1461. doi: 10.1177/00207640231164010. Epub 2023 Apr 10. Int J Soc Psychiatry. 2023. PMID: 37036139
-
Social, personal and medical factors influencing treatment delay for patients with primary glaucoma during the COVID-19 pandemic: a qualitative interview study.BMJ Open. 2025 Mar 29;15(3):e096469. doi: 10.1136/bmjopen-2024-096469. BMJ Open. 2025. PMID: 40157725 Free PMC article.
-
Understanding the reasons why patients delay seeking treatment for oral cancer symptoms from a primary health care professional: an integrative literature review.Eur J Oncol Nurs. 2014 Feb;18(1):118-24. doi: 10.1016/j.ejon.2013.07.005. Epub 2013 Sep 5. Eur J Oncol Nurs. 2014. PMID: 24012186 Review.
-
Duration and determinants of delayed tuberculosis diagnosis and treatment in high-burden countries: a mixed-methods systematic review and meta-analysis.Respir Res. 2021 Sep 23;22(1):251. doi: 10.1186/s12931-021-01841-6. Respir Res. 2021. PMID: 34556113 Free PMC article.
References
-
- Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet (London England). 2021;398(10299):535–54. - PubMed
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49. - PubMed
-
- Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, Wollum A, Sanman E, Wulf S, Lopez AD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. JAMA. 2014;311(2):183–92. - PubMed
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. Cancer J Clin. 2021;71(1):7–33. - PubMed
-
- Giovino GA, Mirza SA, Samet JM, Gupta PC, Jarvis MJ, Bhala N, Peto R, Zatonski W, Hsia J, Morton J, et al. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. Lancet (London England). 2012;380(9842):668–79. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical